 SOMERSET, N.J.--BUSINESS WIRE-- LegendBiotech--Legend Biotech Corporation NASDAQ: LEGN Legend Biotech, a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced today the initiation of a rolling submission of a Biologics License Application BLA to the Food and Drug Administration FDA for ciltacabtagene autoleucel cilta-cel, an investigational B-cell maturation antigen BCMA-directed chimeric an 